smart deal accret buy dip today
acquisit otezla preview prior note posit smart deal deploy
part huge balanc sheet provid ep accret otezla
app went growth top-lin ep compound-annual-growth-rate yet
trade believ stock look even better today go
initi reaction buy dip like go acquir pe
ep con goe
buy dip today stock bounc back outer-year consensu number
like go short-term investor question acquisit cost
otezla net tax benefit higher cite rang
consensu think howev process competit
price go bit benefit excel anyway
enbrel big new inform excel buyer asset grow
busi around world enbrel salesforc lastli
call guid initi opex slightli higher consensu even w/ otezla
opex includ due higher oncolog pipelin obvious kra
spend higher sg ramp around world regardless short-
term stuff long-term stori got better due otezla continu thesi around
otezla deal accret especi make even better
new amgn-otezla app detail accret assumpt otezla
probabl around add
revenu estim ebit margin ep accret
benefici boost revenu ep compound-annual-growth-rate
rev ep growth compound-annual-growth-rate first year mostli integr
minim opex benefit cours guid obviou synergi time given
enbrel salesforc ou especi great synergi humira biosimilar
salesforc japan stand-alon grow infrastructur
increas estim revenu goe
ep goe ep also goe base
synergi henc trade low multipl see pe expans
execut acknowledg otezla deal expect close pend
ftc review think alreadi discuss preliminari review
thing deal go w/o major issu
pleas see analyst certif import disclosur inform inform regard statu non-u analyst
page report
price target base appli
multipl ep
view lower-risk lower-beta higher
visibl biotech move higher benefit
biotech sector see posit rotat
believ consensu estim gener low
next year
upsid scenario price base appli
multipl non-gaap ep
impact neulasta biosimilar launch less
expect onpro devic maintain market share
high visibl largest drug enbrel
sale acceler us/eu
continu better-than-anticip launch aimovig
kra play significantli faster
migrain
better expect
posit tezepelumab data
downsid scenario price base
appli multipl non-gaap ep
greater-than-anticip competit mylan
unfavor legal develop samsung/
sandoz enbrel biosimilar
higher expect price pressur enbrel
slower expect sale reimburs
aimovig launch trajectori neg affect
disappoint kra upcom
kra oncolog program could surpris upsid
bite t-cell engag platform garner attent
next month w/ new data releas
see potenti balanc sheet deploy
aimovig launch trajectori continu strong
believ repatha continu see volum growth
new ndc decreas script abandon rate
think eros entranc neulasta
biosimilar may over-st
updat clinic data kra program oncolog
phase tezepelumab asthma data
new bcma data prove compet
celg
bolt-on larg hedg biosimilar
risk add emerg market exposur
continu strong aimovig growth/launch trajectori
pleas see import disclosur inform page report
compani report jefferi estim
pleas see import disclosur inform page report
figur net incom rate exhibit incom statement
pleas see import disclosur inform page report
fiscal year end figur mm except per incom statementproduct repatha parsabiv- erenumab cgrp biosimilars- even romo otezla kra tezepelumab asthma bcma oncology/bit mn pharma total sale research sell gener total oper interest interest incom incom provis incom net non-gaap ep ep outstand outstand equiti research
global biotechnolog compani focus develop manufactur commerci novel biotherapeut
primarili cancer nephrolog inflammatori diseas cardiovascular diseas bone diseas pioneer use
recombin dna produc world success blockbust biotech drug compani core busi
erythropoietin epo stimul agent esa epogen aranesp neutrophil stimul franchis
neulasta obtain princip inflammatori diseas busi enbrel acquisit immunex go forward
compani primari futur growth driver repatha antibodi target hyperlipidemia
price target base appli histor industri multipl non-gaap ep support
dcf risk includ ip litig biosimilar price competit
pt includ soliris/ultomiri strensiq kanuma risk includ competit
soliris/ultomiri franchis biosimilar complement inhibitor
price target base assumpt announc acquisit celg close price target
support dcf ascrib base busi pipelin remaind pipelin risk includ
neg sharehold vote jeopard acquisit potenti overbid prior close revlimid litig favor gener
regulatory/clin trial setback
michael yee certifi view express research report accur reflect person view subject
secur subject compani also certifi part compens directli indirectli relat
specif recommend view express research report
andrew tsai certifi view express research report accur reflect person view subject
secur subject compani also certifi part compens directli indirectli relat
specif recommend view express research report
kelechi chiker ph certifi view express research report accur reflect person view
subject secur subject compani also certifi part compens directli indirectli
relat specif recommend view express research report
arshad haider certifi view express research report accur reflect person view subject
secur subject compani also certifi part compens directli indirectli relat
specif recommend view express research report
aryeh gold certifi view express research report accur reflect person view subject
secur subject compani also certifi part compens directli indirectli relat
specif recommend view express research report
case jefferi employe analyst respons coverag financi instrument discuss
report receiv compens base part overal perform firm includ invest bank incom seek
updat research appropri variou regul may prevent us asid certain industri report publish
period basi larg major report publish irregular interv appropri analyst judgement
articl articl
pleas see import disclosur inform page report
